UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 1228, 2017

______________

BIOSTAR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

______________

Maryland	001-34708	20-8747899
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

No. 588 Shiji Avenue

Xiangyang City, Shaanxi Province, People’s Republic of China 712046

(Address of Principal Executive Office) (Zip Code)

86-029-33686638

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 5 – Corporate Governance and Management

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

~~(a) On~~The ~~December 12, 2017, Leung King Fai, an independent director of the~~ Board of Directors (the “Board”) of Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), ~~delivered~~appointed aMelissa ~~letter~~Fan Chen to fill the ~~Board,~~vacancy infollowing ~~which~~Leung heKing ~~informed~~Fai’s departure as an independent member of the Board ~~that~~and hethe ~~tendered~~Chair ~~his~~of ~~resignation~~the asBoard’s anAudit ~~independent~~Committee. The Board ~~member~~determined ~~effective~~that Ms. Chen as ofan ~~December~~“independent” ~~12,~~director ~~2017.~~as ~~The~~such ~~Company~~term ~~accepted~~is ~~Leung~~defined ~~King~~under ~~Fai’s~~the ~~resignation~~Nasdaq ~~upon~~Marketplace ~~receipt~~Rules ofand the ~~resignation~~federal ~~letter~~securities laws. AtIn addition, the ~~time~~Board ofappointed ~~his~~Ms. ~~resignation,~~Chen heto ~~served~~serve as the ~~Chairman~~Chair of the Audit Committee. ofFollowing the foregoing appointment, the Board again consists of five members: Ronghua Wang (Chairman), Melissa Fan Chen, Haipeng Wu, Zhanxiang Ma and Qinghua Liu, all but one of whom (Ronghua Wang) are “independent” Board members.

~~Leung~~Presently, ~~King~~Ms. ~~Fai’s~~Chen ~~letter~~is ~~states~~employed at West Park Capital, ina ~~part~~FINRA registered broker-dealer and investment banking firm; Ms. Chen has been employed there since September 2016. From May 2010 to December 2016, ~~that~~Ms. ~~his~~Chen ~~decision~~held the title of Board Secretary and Executive Officer of China Ginseng Holdings, Inc. From May 2012 to ~~resign~~September 2015, Ms. Chen worked as anDirector ~~independent~~of ~~director~~Asian/US ~~was~~Equity ~~made~~markets ~~because~~at ~~his~~Halcyon ~~“director’s~~Cabot ~~fee~~Partners, ~~from~~LLC. 1From ~~January~~September ~~2014~~2015 to ~~present~~February ~~has~~2016, ~~not~~she ~~been~~worked ~~paid~~as a private placement specialist at Olympus Securities LLC.” AFrom ~~copy~~February of2016 ~~Leung~~to ~~King~~September ~~Fai’s~~2016, ~~letter~~she iswas ~~attached~~employed as ~~Exhibit~~an 17equity market/due diligence analyst at Legend Securities, Inc.1 toMs. ~~this~~Chen ~~Current~~holds ~~Report~~Series on7 ~~Form~~and ~~8-K~~63 licenses. She also holds undergraduate (BA) and ~~incorporated~~graduate ~~herein~~(MA) bydegrees ~~reference~~in Accounting from Queens College of the City University of New York.

InThere ~~accordance~~is ~~with~~no ~~the~~arrangement ~~requirements~~or ofunderstanding ~~Item~~between 5Ms.02 ofChen ~~Form~~and ~~8-K,~~any ~~the~~other ~~Company~~persons ~~provided~~pursuant ~~Leung~~to ~~King~~which ~~Fai~~she awas ~~copy~~appointed ofas ~~the~~discussed ~~disclosures~~above. itNor isare ~~making~~there inany ~~this~~family ~~Item~~relationships 5between Ms.02 ~~Form~~Chen ~~8-K~~and any executive officers and directors. Further, there are no ~~later~~transactions ~~than~~involving the ~~day~~Company ofwhich ~~filing~~transaction ~~this~~would ~~Form~~be 8reportable pursuant to Item 404(a) of Regulation S-K ~~with~~promulgated under the Securities ~~and~~Act ~~Exchange~~of ~~Commission~~1933, as amended.

Item 9.01 Financial Statements and Exhibits

~~No.~~(c) ~~Title~~Exhibits.

17NA.~~1 Leung King Fai’s letter resigning from the Biostar Pharmaceuticals, Inc.’s Board of Directors, dated December 12, 2017.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Biostar Pharmaceuticals, Inc.


	By:	/s/ Ronghua Wang
		Ronghua Wang, Chief Executive Officer
		Ronghua Wang, Chief Executive Officer

Date: December 1828, 2017

Filing Compare · Biostar Pharmaceuticals, Inc.